LOSS....THINK U HAVE LOST YOUR MARBELS...LONG AND STRONG GRANNY!
This is how the big boys play???
Who cares moron a loss is a loss great call..
OH LOST GRANNY...THIS NOT THE OTC SWEET CHEEKS!!!!!
Huh closed $2.08
Is this how the big boys play??
REMEMBER THE BUY OUT NEWS 2 YEARS AGO...Make me think theres an offer on the table!
Sweet, and more readouts on other P2/3 in pipeline
wow, nice...shit don't own it
Ultragenyx and Mereo BioPharma Announce Interim Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Setrusumab (UX143) Significantly Reduced Fracture Rates in Patients with Osteogenesis Imperfecta (OI)
Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annualized fracture rate associated with continuous and meaningful improvements in bone mineral density (BMD)
Ultragenyx hosting Analyst Day on Monday, October 16 at 8:30 a.m. ET
NOVATO, Calif., VANCOUVER, British Columbia and LONDON, Oct. 14, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) and Mereo BioPharma Group plc (NASDAQ: MREO) today announced interim data from the Phase 2 portion of the Phase 2/3 Orbit study demonstrating that treatment with setrusumab (UX143) significantly reduced incidence of fractures in patients with OI with at least 6 months of follow-up and continues to demonstrate ongoing and meaningful improvements in lumbar spine bone mineral density (BMD). The data were presented in a late-breaker presentation at the American Society for Bone and Mineral Research 2023 Annual Meeting (ASBMR).
As of the cut-off date and following at least 6 months of treatment with setrusumab, the annualized fracture rate across all 24 patients in the Phase 2 portion of the study was reduced by 67%. In the 2 years prior to treatment with setrusumab all patients experienced at least 1 fracture. The median annualized fracture rate of 0.72 in the 2 years prior to treatment was reduced to 0.00 (n=24, p=0.042) during the mean treatment duration period of 9 months. Following initiation of treatment with setrusumab, 20 patients experienced no radiographic-confirmed fractures, and 4 patients experienced 7 radiographic-confirmed fractures in 5 separate events. These fractures exclude fractures of the fingers, toes, skull, and face consistent with the Phase 3 study design.
“I have not yet encountered a patient with a fragility fracture while on setrusumab, and this may result from setrusumab’s effects on the skeleton, improving the rate of new bone formation and bone quality,” said Gary Gottesman, M.D., Professor of Pediatrics and Medicine, Washington University School of Medicine. “Some of the kids feel well enough they are participating in activities that they might normally avoid and have suffered some relatively minor fractures.”
The reduction in annualized fracture rates was associated with a clinically meaningful increase in BMD. At the 6-month timepoint, treatment with setrusumab resulted in a mean increase in lumbar spine BMD from baseline of 13% at 20 mg/kg (n=11) and 16% at 40 mg/kg (n=8), which represents the same substantial mean improvement in Z-score of +0.85 for both dose groups at 6 months compared to a combined mean baseline Z-score of –1.68. The small apparent difference in BMD change from baseline is likely related to differences in patients assigned to the two treated groups. There was no statistically significant difference in BMD percent change or Z-score change from baseline between the 20 and 40 mg/kg dosing cohorts.
“These data provide compelling evidence that improved bone mineral density, resulting from this unique mechanism of action, reduced the risk of fractures and that treatment with setrusumab could allow patients with OI to lead much more active lives with fewer fractures,” said Eric Crombez, M.D., chief medical officer at Ultragenyx. “I want to acknowledge the OI community and especially thank the people living with OI and their caregivers who have aided the setrusumab development program so that we may potentially offer the first approved treatment option for this severe and disabling disease.”
As of the data cut-off, there were no treatment-related serious adverse events observed in the study. Reported adverse events were generally consistent with those observed in the ASTEROID study with infusion-related events and headache determined to be the most common adverse events related to the study drug. There have been no reported hypersensitivity reactions related to setrusumab. There were no notable safety-related differences observed between dosing groups or age groups.
The Phase 3 portion of the study is currently enrolling approximately 195 patients at 50 sites across 12 countries.
U.S. residents can learn more by visiting ultraclinicaltrials.com.
Analyst Day and Webcast Information
Ultragenyx will host an Analyst Day at 8:30 a.m. ET on Monday, October 16, 2023 to discuss these data and to provide an update on the company’s development pipeline. A live video webcast of the program will be available at https://www.webcaster4.com/Webcast/Page/359/49192.
An archived version of the remarks will also be available through the Ultragenyx website.
The Setrusumab Phase 3 Program
The global, seamless Phase 2/3 Orbit study is evaluating the effect of setrusumab on clinical fracture rate in patients aged 5 to <26 years. In the Phase 2 portion, 24 patients were randomized 1:1 to receive setrusumab at one of two doses to determine the optimal dosing strategy for Phase 3. The pivotal Phase 3 portion of the study will include approximately 195 patients at 50 sites across 12 countries, randomized 2:1 to receive setrusumab or placebo, with a primary efficacy endpoint of annualized clinical fracture rate, excluding fingers, toes, skull, and face. All patients will transition to an extension period and receive open-label setrusumab after the Phase 3 primary analysis is complete.
The global Phase 3 Cosmic study is an open-label, randomized, active-controlled study in patients aged 2 to <7 years evaluating setrusumab compared to intravenous bisphosphonates (IV-BP) therapy on reduction in total fracture rate, including morphometric vertebral fractures. The Cosmic study will enroll approximately 65 patients at more than 20 sites across 8 countries.
About Osteogenesis Imperfecta (OI)
Osteogenesis Imperfecta (OI) includes a group of genetic disorders impacting bone metabolism. Approximately 85% to 90% of OI cases are caused by mutations in the COL1A1 or COL1A2 genes, leading to either reduced or abnormal collagen and changes in bone metabolism. The collagen mutations in OI can result in increased bone brittleness, which contributes to a high rate of fractures. Patients with OI also exhibit inadequate production of new bone, which leads to decreased bone mass, bone fragility and weakness. OI can also lead to bone deformities, abnormal spine curvature, pain, decreased mobility, and short stature. No treatments are approved for OI, which affects approximately 60,000 people in the developed world.
About Setrusumab (UX143)
Setrusumab is a fully human monoclonal antibody that inhibits sclerostin, a negative regulator of bone formation. Blocking sclerostin is expected to increase new bone formation, bone mineral density and bone strength in OI. In mouse models of OI, the use of anti-sclerostin antibodies was shown to increase bone formation, improve bone mass to normal levels, and increase bone strength against fracture force testing to normal levels.
In 2019 Mereo BioPharma completed the Phase 2b dose-finding study (ASTEROID) for setrusumab in 112 adults with OI. The ASTEROID study demonstrated treatment with setrusumab resulted in a clear, dose-dependent and statistically significant effect on bone formation and bone density at multiple anatomical sites among adult participants with OI.
Ultragenyx and Mereo BioPharma are collaborating on the development of setrusumab globally based on the collaboration and license agreement between the parties. The companies have developed a comprehensive late-stage program to continue development of setrusumab in pediatric and young adult patients across OI sub-types I, III and IV.
Ultragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultra-rare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease.
The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency. For more information on Ultragenyx, please visit ultragenyx.com.
About Mereo BioPharma
Mereo BioPharma is a biopharmaceutical company focused on the development of innovative therapeutics for rare diseases. The Company has two rare disease product candidates, setrusumab for the treatment of Osteogenesis Imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1-antitrypsin deficiency-associated lung disease (AATD-LD). The Co
WHEN THE BAKER BROS INVEST IN A STOCK, YA BETTER HOP ON.On July 31, 2023, BAKER BROS. ADVISORS LP purchased 14,604,391 shares of Mereo BioPharma Group PLC at a price of $1.33 per share. This transaction had an impact of 0.11 on the firm's portfolio. Following this acquisition, BAKER BROS. ADVISORS LP now holds a total of 14,604,391 shares in Mereo BioPharma Group PLC, representing 2.20% of the company's total shares...
ohhhh, you know what down lo is. you are about that life. don't play coy.
keep watching...its about to fly!!!
ohhhh, you know what down lo is. you are about that life. don't play coy.
what kind of English is that, you said you went to college..lol...watch and learn how its done!!
you are the really dummy, bozo the repressed and down lo.
Sure. 8 months of holding a bag… lol
Boom that’s how ya read a chart numnuts
Like I said… 8 months holding a bag for small move it’s meh.
You forget we can see all your postssss. He he
lmao..say hello to 1.65 dummy
Ugh. I’ll let you continue to embarrass your self…
BAG OF GOLD...WATCH AND LEARN...BACK TO PUMPING MONI SON
LMAO..WATCH AND LEARN
Great Refresher link, TY :) …keep eyes on BLUE—bla was sub’d 4/24 or so, expect over next week to hear yay or nay on Acceptance and/ or fast track ( 6mos. For pdufa date) or 10mos. If not ( key being accepted) … if denied, delay of prob 6mos-1yr!!! They burn crap load of cash, so an equity raise a certain… downside $2, upside could go parabolic to Double digits (24% shorties)
For sure, climbing steps and with a deep pipe bench/ late stage(s), readouts in Q3/4 could propel to the $5 target (Needham) GLTA
Thanks for that link. The FDA is the biggest government scam in this Solar System. Not only do they fleece trillions from the biotech sector but if you really want approval then bribes and payola will help.
Too bad the FDA didn't follow the protocol for the 'Vaccine'. Over 50 million dead worldwide. Have to dig for those numbers these days, but they're real.
Classic signs of accumulation on chart. I have had this on my radar since .58. Biotech was the most beaten and should have a spectacular recovery.
Good luck to us.
SONIC BOOM $MREO
15% in 3 months… what a waste of time when I am chasing bangers… :)
patience is a traders virtue...not otc rinse scams
Ouch. Still no $1.65 3 months later? BAHAHA. Dude.. come on now
Good luck today, prosperous trading!
NP it's all good. Thanks for the heads up on TARA. :)
TY! And I sorta made this reply on Forza thread( by mistake), so here it is on this one:
And good luck with this play, hopefully J.Visconti delivers for y’all ! :) ….somebody I know :)
Take a look at TARA( bio- low float, $90m in cash..under $3 … 3 or so drugs in pipe